Summary:
Haematopoietic stem cell transplantation (HSCT) has been used recently as an effective therapy in patients with resistant rheumatoid arthritis (RA). Although disease control occurs in the majority of cases, recurrence is common, often coinciding with B-cell reconstitution. We hypothesized that Rituximab, a monoclonal anti-CD20 antibody, would have activity in this group of patients. We treated 10 RA patients (8F:2M, median age 46.5 years), who had recurrent disease post HSCT. All patients received two doses of Rituximab 1 g, 2 weeks apart with no major adverse sequelae and were followed for 12 months. A total of eight out of 10 patients experienced major clinical responses as measured by the American College of Rheumatology (ACR) criteria, with 50–70% improvement in disease parameters. Responses were equivalent to previous responses attained with HSCT. Disease responses were maximal at 4–8 months post Rituximab and correlated with B-cell lymphopenia and a reduction of rheumatoid factor titre. Disease recurrence occurred in 6/9 responders within 12 months and four patients were subsequently retreated, with major responses again attained. This study provides further evidence that B-cell depletion leads to a significant improvement in disease activity in patients with severe RA and provides data for future trials of HSCT and Rituximab therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Snowden J, Passweg J, Moore J et al. Autologous haemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheum 2004; 31: 482–488.
Traynor AE, Barr WG, Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002; 46: 2917–2923.
Moore J, Brooks P, Milliken S et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301–2309.
Verburg RJ, Kruize AA, van den Hoogen FH et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001; 44: 754–760.
Edwards JC, Cambridge G . Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol 2001; 40: 205–211.
Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–735.
Snowden JA, Biggs JC, Milliken ST et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42: 2286–2292.
Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–1939.
Lacki JK, Schochat T, Sobieska M et al. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 1994; 53: 76–82.
Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748–752.
Leandro MJ, Edwards JC, Cambridge G . Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883–888.
Amano H, Morimoto S, Kaneko H et al. Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 2000; 9: 26–32.
Koetz K, Bryl E, Spickschen K et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci 2000; 97: 9203–9208.
Uitdehaag BMJ, Nillesen WM, Hommes OR . Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand 1989; 79: 12–17.
Neumann V, Hopkins R, Dixon J et al. Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. Ann Rheum Dis 1985; 44: 747–751.
Vita SD, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029–2033.
Acknowledgements
We thank the Trial nurse coordinators for their invaluable help throughout the study. We would like to acknowledge the care provided to all patients by the nursing staff and resident medical staff of St Vincents Hospital and Royal Perth Hospital. This work was supported (in part) by research funding from Roche Pharmaceuticals to the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moore, J., Ma, D., Will, R. et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34, 241–247 (2004). https://doi.org/10.1038/sj.bmt.1704570
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704570
Keywords
This article is cited by
-
NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes
Autoimmunity Highlights (2020)
-
A comprehensive review of rituximab therapy in rheumatoid arthritis patients
Clinical Rheumatology (2019)
-
Cells of the Immune System Orchestrate Changes in Bone Cell Function
Calcified Tissue International (2014)
-
Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy
Annals of Hematology (2012)
-
Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?
Clinical Reviews in Allergy & Immunology (2008)